• Je něco špatně v tomto záznamu ?

COVID-19 vaccine booster significantly decreases the risk of intensive care unit hospitalization in heart failure patients during the Omicron variant wave: A population-based study

J. Parenica, K. Benesova, M. Radvan, O. Sanca, J. Hlasensky, P. Lokaj, T. Ondrus, K. Helanova, P. Kala, L. Dusek, J. Jarkovsky

. 2022 ; 9 (-) : 998842. [pub] 20221020

Status neindexováno Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22031482

BACKGROUND: Heart failure (HF) patients are at higher risk of severe coronavirus disease 2019 (COVID-19). The Omicron variant has many novel mutations including those in the spike protein, leading to questions about vaccine effectiveness. The aim of this analysis was to evaluate the effectiveness of the COVID-19 vaccine with or without a booster (i.e., after the third dose) during the Omicron variant wave. METHODS: Chronic heart failure patients in the Czech Republic were included in the analysis. COVID-19 infection was monitored from January 1st 2022 to March 31st 2022. The analysis was conducted on data collected in the National Health Information System. Vaccine effectiveness of vaccinated (with or without booster) vs. unvaccinated patients was analyzed for incidence of COVID-19, COVID-19-related hospitalizations, COVID-19 related intensive care unit admissions, and COVID-19 related mechanical ventilation/extracorporeal membrane oxygenation treatment. FINDINGS: From a total 165,453 HF patients in the Czech Republic, 9,728 contracted COVID-19 (22.9% of them not vaccinated, 23.2% vaccinated and 53.8% vaccinated and boosted). Risk of intensive care unit (ICU) hospitalization was 7.6% in the unvaccinated group, 4.8% in the vaccinated group and 2.9% in the boosted group. The calculated effectiveness of the COVID-19 vaccine in prevention of ICU hospitalization in the vaccinated group was 41.9 and 76.6% in the boosted group. INTERPRETATION: The results demonstrated moderate vaccine effectiveness in the prevention of severe COVID-19 in vaccinated but not boosted HF patients. Much stronger effectiveness was found in those who were vaccinated and boosted.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22031482
003      
CZ-PrNML
005      
20230127131202.0
007      
ta
008      
230119s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fcvm.2022.998842 $2 doi
035    __
$a (PubMed)36337877
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Parenica, Jiri $u Internal and Cardiology Department, University Hospital Brno, Brno, Czechia $u Faculty of Medicine, Masaryk University, Brno, Czechia
245    10
$a COVID-19 vaccine booster significantly decreases the risk of intensive care unit hospitalization in heart failure patients during the Omicron variant wave: A population-based study / $c J. Parenica, K. Benesova, M. Radvan, O. Sanca, J. Hlasensky, P. Lokaj, T. Ondrus, K. Helanova, P. Kala, L. Dusek, J. Jarkovsky
520    9_
$a BACKGROUND: Heart failure (HF) patients are at higher risk of severe coronavirus disease 2019 (COVID-19). The Omicron variant has many novel mutations including those in the spike protein, leading to questions about vaccine effectiveness. The aim of this analysis was to evaluate the effectiveness of the COVID-19 vaccine with or without a booster (i.e., after the third dose) during the Omicron variant wave. METHODS: Chronic heart failure patients in the Czech Republic were included in the analysis. COVID-19 infection was monitored from January 1st 2022 to March 31st 2022. The analysis was conducted on data collected in the National Health Information System. Vaccine effectiveness of vaccinated (with or without booster) vs. unvaccinated patients was analyzed for incidence of COVID-19, COVID-19-related hospitalizations, COVID-19 related intensive care unit admissions, and COVID-19 related mechanical ventilation/extracorporeal membrane oxygenation treatment. FINDINGS: From a total 165,453 HF patients in the Czech Republic, 9,728 contracted COVID-19 (22.9% of them not vaccinated, 23.2% vaccinated and 53.8% vaccinated and boosted). Risk of intensive care unit (ICU) hospitalization was 7.6% in the unvaccinated group, 4.8% in the vaccinated group and 2.9% in the boosted group. The calculated effectiveness of the COVID-19 vaccine in prevention of ICU hospitalization in the vaccinated group was 41.9 and 76.6% in the boosted group. INTERPRETATION: The results demonstrated moderate vaccine effectiveness in the prevention of severe COVID-19 in vaccinated but not boosted HF patients. Much stronger effectiveness was found in those who were vaccinated and boosted.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Benesova, Klara $u Department of Data Collection and Processing, Institute of Health Information and Statistics of the Czech Republic, Prague, Czechia $u Faculty of Medicine, Institute of Biostatistics and Analysis, Masaryk University, Brno, Czechia
700    1_
$a Radvan, Martin $u Internal and Cardiology Department, University Hospital Brno, Brno, Czechia $u Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Sanca, Ondrej $u Department of Data Collection and Processing, Institute of Health Information and Statistics of the Czech Republic, Prague, Czechia $u Faculty of Medicine, Institute of Biostatistics and Analysis, Masaryk University, Brno, Czechia
700    1_
$a Hlasensky, Jiri $u Internal and Cardiology Department, University Hospital Brno, Brno, Czechia $u Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Lokaj, Petr $u Internal and Cardiology Department, University Hospital Brno, Brno, Czechia $u Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Ondrus, Tomas $u Internal and Cardiology Department, University Hospital Brno, Brno, Czechia $u Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Helanova, Katerina $u Internal and Cardiology Department, University Hospital Brno, Brno, Czechia $u Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Kala, Petr $u Internal and Cardiology Department, University Hospital Brno, Brno, Czechia $u Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Dusek, Ladislav $u Department of Data Collection and Processing, Institute of Health Information and Statistics of the Czech Republic, Prague, Czechia $u Faculty of Medicine, Institute of Biostatistics and Analysis, Masaryk University, Brno, Czechia
700    1_
$a Jarkovsky, Jiri $u Department of Data Collection and Processing, Institute of Health Information and Statistics of the Czech Republic, Prague, Czechia $u Faculty of Medicine, Institute of Biostatistics and Analysis, Masaryk University, Brno, Czechia
773    0_
$w MED00198704 $t Frontiers in cardiovascular medicine $x 2297-055X $g Roč. 9, č. - (2022), s. 998842
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36337877 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230119 $b ABA008
991    __
$a 20230127131153 $b ABA008
999    __
$a ok $b bmc $g 1889511 $s 1182815
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2022 $b 9 $c - $d 998842 $e 20221020 $i 2297-055X $m Frontiers in cardiovascular medicine $n Front Cardiovasc Med $x MED00198704
LZP    __
$a Pubmed-20230119

Najít záznam

Citační ukazatele

Možnosti archivace